FibroBiologics' CEO to speak at A4LI's H-SPAN Summit on advancing longevity science and therapeutic innovations.
Quiver AI Summary
FibroBiologics, Inc., a clinical-stage biotechnology company specializing in therapeutics for chronic diseases, announced that its Chairman and CEO, Pete O’Heeron, will speak at the upcoming A4LI’s H-SPAN Summit at Georgetown University from June 29 to July 1, 2026. The summit aims to gather leaders and innovators to discuss legislative and scientific initiatives for enhancing human healthspan. O’Heeron is expected to address advancements in longevity science and cellular therapeutics, highlighting FibroBiologics' commitment to innovation in chronic disease treatment. The event underscores the increasing importance of collaboration between scientific advancement and policy, with a focus on longevity research and advocacy efforts. The Alliance for Longevity Initiatives (A4LI), organizing the summit, is dedicated to promoting legislative actions to extend healthy human lifespans.
Potential Positives
- Chairman and CEO Pete O’Heeron has been invited to serve as a main stage speaker at the prestigious A4LI’s H-SPAN Summit, enhancing the company's visibility and reputation in the biotechnology sector.
- FibroBiologics' involvement in discussions focused on longevity science aligns with current trends in healthcare, positioning the company as a leader in addressing chronic diseases and pioneering innovative therapeutic approaches.
- The summit offers a platform for networking with key stakeholders, including researchers, biotech executives, and policymakers, potentially leading to collaborations and increased support for FibroBiologics' initiatives.
- Public recognition of the company’s commitment to advancing therapies for chronic diseases and extending human life can bolster investor confidence and attract interest in its future developments.
Potential Negatives
- There is no mention of any recent clinical trial results or advancements in product development, which may raise concerns about the company's progress and competitiveness in the biotechnology sector.
FAQ
What is the H-SPAN Summit?
The H-SPAN Summit is a premier event focused on advancing longevity initiatives and healthspan policies, hosted by A4LI.
Who is speaking at the H-SPAN Summit?
Pete O’Heeron, Chairman and CEO of FibroBiologics, has been invited as a main stage speaker at the summit.
When is the H-SPAN Summit taking place?
The H-SPAN Summit will be held from June 29 to July 1, 2026, at Georgetown University.
What topics will be covered at the summit?
The summit will discuss longevity research, innovation policy frameworks, and advocacy for healthspan priorities.
How does FibroBiologics contribute to longevity science?
FibroBiologics develops therapies for chronic diseases and promotes research in cellular therapeutics to extend human lifespan.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$FBLG Insider Trading Activity
$FBLG insiders have traded $FBLG stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $FBLG stock by insiders over the last 6 months:
- RUBEN A GARCIA (General Counsel) purchased 140,000 shares for an estimated $47,600
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$FBLG Hedge Fund Activity
We have seen 21 institutional investors add shares of $FBLG stock to their portfolio, and 35 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- LANDSCAPE CAPITAL MANAGEMENT, L.L.C. added 350,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $191,170
- YORKVILLE ADVISORS GLOBAL, LP removed 334,316 shares (-39.6%) from their portfolio in Q3 2025, for an estimated $182,603
- BLACKROCK, INC. removed 311,125 shares (-41.4%) from their portfolio in Q3 2025, for an estimated $169,936
- GTS SECURITIES LLC added 308,661 shares (+inf%) to their portfolio in Q3 2025, for an estimated $168,590
- AMG NATIONAL TRUST BANK added 138,960 shares (+inf%) to their portfolio in Q4 2025, for an estimated $31,252
- GOLDMAN SACHS GROUP INC removed 121,074 shares (-92.0%) from their portfolio in Q3 2025, for an estimated $66,130
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 106,100 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $57,951
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$FBLG Analyst Ratings
Wall Street analysts have issued reports on $FBLG in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 01/06/2026
- HC Wainwright & Co. issued a "Buy" rating on 01/02/2026
To track analyst ratings and price targets for $FBLG, check out Quiver Quantitative's $FBLG forecast page.
$FBLG Price Targets
Multiple analysts have issued price targets for $FBLG recently. We have seen 2 analysts offer price targets for $FBLG in the last 6 months, with a median target of $10.0.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $15.0 on 01/06/2026
- Matthew Caufield from HC Wainwright & Co. set a target price of $5.0 on 01/02/2026
Full Release
HOUSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Chairman and CEO Pete O’Heeron has been invited to serve as a main stage speaker at the upcoming A4LI’s H-SPAN Summit at Georgetown University.
The summit, taking place June 29–July 1, 2026, is hosted by the Alliance for Longevity Initiatives (A4LI) and is recognized as a premier event bringing together leaders, innovators, policymakers, and advocates from across the globe to advance legislative and scientific initiatives aimed at promoting healthier human lifespans. The three-day event will be held on the Georgetown University Capitol Campus and will culminate in a Congressional Briefing and Hill Day on Capitol Hill.
“We are proud to have Pete represent FibroBiologics on the H-SPAN stage,” said Dylan Livingston, Founder/CEO of Alliance For Longevity Initiatives. “Thymic regenerative biology is a potentially transformative area of research for extending healthy human lifespan, and Pete is a trailblazer in this space. FibroBiologics’ commitment to addressing chronic diseases aligns directly with the goals of the summit and A4LI’s mission of accelerating innovation that extends human healthspan.”
At the summit, Mr. O’Heeron will address an expert audience of researchers, biotech executives, and policy leaders on the next frontier of longevity science, including breakthroughs in cellular therapeutics and strategies for translating research into real-world clinical impact.
The Summit unites scientific advancement with policy frameworks, with Day 1 focusing on cutting-edge longevity research, Day 2 on frameworks for innovation policy, and Day 3 on direct advocacy with members of Congress to elevate national healthspan priorities. This year’s agenda reflects growing momentum in the biotech longevity ecosystem and underscores the importance of cross-sector collaboration.
“I’m honored to be selected as one of the main stage speakers for the H-SPAN Summit and to contribute to this important national dialogue,” said Pete O’Heeron. “FibroBiologics is committed to advancing therapies that prevent and treat chronic disease along with extending human life, and summits like this are essential for aligning scientific innovation with policy action.”
The Alliance for Longevity Initiatives (A4LI) is a 501(c)(4) organization advancing legislation and policies that aim to increase healthy human lifespan and accelerate equitable access to next-generation therapies. The H-SPAN Summit has quickly become a leading forum for shaping America’s longevity policy agenda.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com .
General Inquiries:
[email protected]
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
[email protected]
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
[email protected]
For more information on A4LI’s H-SPAN Summit at Georgetown University or to register, visit: https://a4li.org/h-span-summit-dc/
